logo
  

Incyte, MorphoSys Say First Patient Dosed In Phase 3 InMIND Study On Follicular Lymphoma

Incyte (INCY) and MorphoSys AG (MOR) said that the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).

On January 7, the U.S. Food and Drug Administration granted orphan drug designation to tafasitamab for the treatment of follicular lymphoma.

Follicular lymphoma and marginal zone lymphoma are the most common indolent, or slow growing, forms of B-Cell non-Hodgkin lymphomas.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Viona Pharmaceuticals Inc. has recalled type 2 diabetes drug Metformin in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Ford Motor Co. on Monday issued a recall for a total of 19,626 2021 F-Series Super Duty vehicles with dual rear wheels in North America. These include 17,616 vehicles in the U.S. and federal territories; 1,779 in Canada; and 231 in Mexico. The affected vehicles are equipped with front-wheel hub extenders... Royal Philips has recalled specific sleep and respiratory care devices due to the potential health risks related to the polyester-based polyurethane or PE-PUR sound abatement foam component. The affected products include Bi-Level Positive Airway Pressure or Bi-Level PAP, Continuous Positive Airway Pressure or CPAP, and mechanical ventilator devices.
Follow RTT